Phase II study of dovitinib in patients with metastatic and|[sol]|or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib

Y-K Kang; C Yoo; B-Y Ryoo; J J Lee; E Tan; I Park; J H Park; Y J Choi; J Jo; J-S Ryu; M-H Ryu

首页> 外文期刊>British Journal of Cancer >Phase II study of dovitinib in patients with metastatic and|[sol]|or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib

【24h】

Phase II study of dovitinib in patients with metastatic and|[sol]|or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib

机译：伊马替尼和舒尼替尼治疗失败后转移性和[或] [或]不可切除的胃肠道间质瘤患者中多维替尼的II期研究

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background:This prospective, phase II trial evaluated the efficacy and safety of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours (GISTs) after failure of at least imatinib and sunitinib.

机译：背景：这项前瞻性II期临床试验评估了至少接受伊马替尼和舒尼替尼治疗失败的转移性和/或不可切除的胃肠道间质瘤（GIST）患者中多威替尼的疗效和安全性。

著录项

来源
《British Journal of Cancer》 |2013年第9期|共7页
作者
Y-K Kang; C Yoo; B-Y Ryoo; J J Lee; E Tan; I Park; J H Park; Y J Choi; J Jo; J-S Ryu; M-H Ryu;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): A randomised, placebo-controlled, phase 3 trial [J] . KangY.-K., RyuM.-H., YooC., The lancet oncology . 2013,第12期

机译：伊马替尼和舒尼替尼治疗失败后恢复伊马替尼以控制转移性或不可切除的胃肠道间质瘤（右）：一项随机，安慰剂对照的3期试验
2. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial [J] . Doi Toshihiko, Kurokawa Yukinori, Sawaki Akira, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：TAS-116的功效和安全性，一种热休克蛋白90的口服抑制剂，在转移或不可切除的胃肠间质谱难以难治于伊马替尼，孙尼替尼和雷诺苯脲：II期，单臂试验
3. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: A multicenter phase II trial [J] . GeorgeS., WangQ., HeinrichM.C., Journal of Clinical Oncology . 2012,第19期

机译：伊马替尼和舒尼替尼治疗失败后转移性和/或不可切除的胃肠道间质瘤患者瑞戈非尼的疗效和安全性：一项多中心II期试验
4. Preliminary results of a phase I/II clinical trial using in situ photoimmunotherapy combined with imiquimod for metastatic melanoma patients [C] . Xiaosong Li, Mark F. Naylor, Robert E. Nordquist, . 2010

机译：使用原位光免疫疗法联合咪喹莫特治疗转移性黑色素瘤患者的I / II期临床试验的初步结果
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib [O] . Y-K Kang, C Yoo, B-Y Ryoo, 2013

机译：伊马替尼和舒尼替尼治疗失败后转移性和/或不可切除的胃肠道间质瘤患者的多维替尼II期研究
7. Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial [O] . Suzanne George, Qian Wang, Michael C. Heinrich, 2012

机译：伊马替尼和孙尼替尼失效后，雷龙蒽苯磺因患者的疗效和安全性：多中心第二期试验

Phase II study of dovitinib in patients with metastatic and|[sol]|or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅